Available IPD datapackage for study 'A Multicenter, Phase III, Open-Label, Randomized Study in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia to Evaluate the Benefit of Venetoclax (GDC-0199/ABT-199) Plus Rituximab Compared With Bendamustine Plus Rituximab'

Name: Available IPD datapackage for study 'A Multicenter, Phase III, Open-Label, Randomized Study in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia to Evaluate the Benefit of Venetoclax (GDC-0199/ABT-199) Plus Rituximab Compared With Bendamustine Plus Rituximab'
Creator: Vivli
Published: 2026-04-15 16:08:10
License: 暂无描述

DataCite Commons2026-04-15 更新2026-05-07 收录

下载链接：

https://search.vivli.org/doiLanding/dataPackages/PR00007555.0

下载链接

链接失效反馈

官方服务：

资源简介：

The purpose of this open-label, multicenter, randomized, Phase III study is to evaluate the benefit of venetoclax in combination with rituximab compared with bendamustine in combination with rituximab in participants with relapsed or refractory CLL. Participants will be randomly assigned in 1:1 ratio to receive either venetoclax + rituximab (Arm A) or bendamustine + rituximab (Arm B).

提供机构：

Vivli

创建时间：

2026-04-15